PCOS Is Now PMOS: What This Name Change Means for Patients

In May 2026, polycystic ovary syndrome (PCOS) was officially renamed polyendocrine metabolic ovarian syndrome (PMOS) after a years-long international effort. The change affects roughly 1 in 8 women, along with the clinicians who care for them and the researchers studying the condition. This guide explains what changed, why experts say the old name was misleading, and what the rename actually means for people currently living with the condition or seeking a diagnosis. The information here is educational and is not a substitute for evaluation by a licensed clinician.

What Is PMOS (Formerly PCOS)?

PMOS is a hormonal disorder affecting an estimated 1 in 8 women globally, making it one of the most common endocrine conditions in people assigned female at birth. While the old name focused attention on the ovaries, the condition actually involves disruptions across multiple hormone systems and affects metabolism, weight, fertility, skin, and mental health.

Common signs of PMOS include irregular periods, excess hair growth (called hirsutism), persistent acne, weight changes, signs of insulin resistance, and fertility challenges. For a deeper look at how these symptoms typically present, our overview of PCOS symptoms, causes, and treatments remains clinically accurate under the new name. Not everyone with PMOS experiences all of these, and the presentation can vary significantly from person to person, which is one reason diagnosis has historically been complicated.

According to the World Health Organization, up to 70 percent of people with PMOS are undiagnosed. Experts believe part of that diagnostic gap traces directly back to the old name and the misconceptions it created. When patients and even some clinicians believed the condition was primarily about ovarian cysts, the broader hormonal and metabolic picture was often missed.

Why PCOS Was Renamed

The term "polycystic" was medically inaccurate, and that was the central problem. People with the condition do not actually have abnormal cysts on their ovaries. What appears on ultrasound is a high number of "arrested follicles," meaning eggs that have failed to fully mature due to hormonal disruption.

This distinction matters. True pathological ovarian cysts are something different entirely. They can grow large, rupture, bleed, cause pain, and sometimes require surgery to treat. Research from Dr. Helena Teede and colleagues, published in JAMA Internal Medicine, has shown that people with the condition are no more likely to have these pathological cysts than people without it. The "cysts" most people associate with PCOS were never really cysts at all.

The old name also created a narrow framing problem. By focusing attention on the ovaries, it implied the condition was primarily gynecological, when in reality it involves multiple hormone systems and affects many parts of the body. Research, funding, and medical education historically emphasized the reproductive aspects of the condition, which left knowledge gaps among doctors in other specialties who were also seeing patients affected by metabolic, dermatologic, and mental health symptoms.

Calls to rename the condition date back to the 1990s. In 2012, the U.S. National Institutes of Health formally recommended a name change, with NIH experts writing that the name PCOS focused on a criterion "which is neither necessary nor sufficient to diagnose the syndrome." It has taken more than a decade since that recommendation for an international consensus name to be agreed on and announced.

What Does PMOS Stand For?

The new name is built from four parts, each of which reflects something specific about the condition.

Poly (meaning "many") signals that the condition involves multiple body systems and multiple hormone disruptions, rather than a single isolated issue. The old name used "poly" to refer to cysts. The new name uses it to refer to the breadth of what the condition actually affects.

Endocrine refers to the hormone-producing systems of the body. This part of the name acknowledges that PMOS is fundamentally a hormonal disorder, not just a reproductive one. It reflects the involvement of androgens, insulin, and other endocrine pathways that have always been part of the clinical picture but were obscured by the old name.

Metabolic captures the strong link between PMOS and metabolic features. Insulin resistance, weight changes, and increased risk of type 2 diabetes and cardiovascular disease are central features of the condition, not side issues. Putting "metabolic" in the name elevates this dimension of the condition to where it has always belonged.

Ovarian Syndrome retains a connection to the ovaries, where some signs are visible on ultrasound, while moving away from the inaccurate "cysts" framing. The word "ovarian" was deliberately chosen over "reproductive." Dr. Teede explained that in many cultures, a woman's worth is unfairly linked to her fertility, so a name implying reproductive impairment was seen as potentially stigmatizing.

How the Decision Was Made

The renaming effort was chaired by Dr. Helena Teede, an endocrinologist and professor of women's health at Monash University in Australia who also directs the Monash Centre for Health Research and Implementation. The work involved 56 academic, clinical, and patient organizations from around the world.

This was not a small expert committee making a decision behind closed doors. The process surveyed thousands of people living with the condition globally, along with thousands of healthcare professionals. Patient advocacy groups were involved at every stage. According to a recent survey published in The Lancet's eClinicalMedicine, nearly 86 percent of patients and 76 percent of health professionals who responded agreed that the name should change.

When asked whether the acronym should remain "PCOS" for ease of adoption, or whether the name should accurately reflect the disease's features, respondents prioritized accuracy. That preference is what produced the change rather than a softer cosmetic update.

The new name was announced in The Lancet on May 12, 2026, and formally presented at the European Society of Endocrinology Conference in Prague. There is a deliberate three-year plan to raise awareness and adopt the new terminology across clinical practice, including updates to medical education and the language used during diagnostic ultrasounds.

What This Name Change Means for Diagnosis and Care

The most important thing to understand is that the condition itself has not changed. If you have been diagnosed with PCOS, you have the same condition under the new name PMOS. Existing diagnoses remain valid, and your current treatment plan does not automatically need to change as a result of the rename.

What is expected to change is the language clinicians use. Ultrasound terminology, in particular, will shift away from "polycystic ovarian morphology" toward language that more accurately describes the arrested follicles being observed. Diagnostic criteria are also expected to evolve, though the fundamental approach (clinical signs, hormone testing, and imaging) remains.

Care may also become more integrated across specialties over time. By explicitly naming the metabolic and endocrine dimensions of the condition, the new terminology may encourage clinicians outside gynecology, including endocrinologists, primary care providers, and dermatologists, to recognize and treat PMOS more readily. Treatment options for PMOS continue to include lifestyle adjustments, hormonal medications, insulin-sensitizing medications, and fertility-focused interventions when relevant.

For people who have suspected they have PCOS but never been formally evaluated, the renewed attention from the rename is an opportunity to seek diagnosis. Speaking with a primary care provider or online gynecologist is a reasonable starting point. Because PMOS involves multiple hormone systems, understanding when to get tested for a hormone imbalance can also help guide that initial conversation. PMOS is treatable, and addressing it can meaningfully improve symptoms across multiple body systems. But evaluation by a clinician is the necessary first step.

Common Questions People Are Asking About the Rename

"Do I need to update my medical records?" In most cases, no. Healthcare providers and electronic health record systems will be updating terminology as part of the three-year rollout. If you want clarity on how your specific record will be updated, you can ask your clinician at your next visit.

"Will my treatment change?" Not as a direct result of the rename. Treatment for PMOS continues to be tailored to individual symptoms and goals, which may include lifestyle adjustments, hormonal therapy, medications that improve insulin sensitivity, and care for specific concerns like acne, hair growth, or fertility.

"Is there a male version of PMOS?" Some researchers have noted that males with low androgen levels can experience similar hormonal and metabolic patterns, including insulin resistance and certain mental health concerns. However, Dr. Teede has publicly said it is too early to formally call this a male form of PMOS, and the science is not yet settled. The condition as currently defined has reproductive implications that differ significantly between sexes.

"Where can I find reliable information?" The AskPCOS app, developed at Monash University and soon to be renamed AskPMOS, is one resource the name-change leadership team has publicly recommended for evidence-based information.

Frequently Asked Questions About PMOS (Formerly PCOS)

Q1: Is PMOS the same condition as PCOS?

Yes. PMOS is simply the new name for the condition formerly known as PCOS. The underlying disorder is the same. The name was changed because experts and patients agreed the old name was inaccurate and misleading about what the condition actually involves.

Q2: When did PCOS officially become PMOS?

The new name was announced in The Lancet on May 12, 2026, with formal presentation at the European Society of Endocrinology Conference in Prague. A three-year rollout plan will phase in adoption across medical practice, research, and patient education.

Q3: Why was the name "polycystic" considered inaccurate?

People with the condition do not have abnormal ovarian cysts. What appears on ultrasound is actually a high number of arrested follicles, which are immature eggs that did not develop properly due to hormonal disruption. True pathological cysts are a different medical issue entirely.

Q4: Do I need to do anything if I already have a PCOS diagnosis?

No immediate action is required. Your existing diagnosis and treatment plan remain valid. Over the next three years, your healthcare provider's terminology may shift to reflect the new name, but the underlying condition and care approach do not change automatically.

Q5: Does the new name change how PMOS is diagnosed?

The diagnostic criteria are expected to be updated over time, particularly the ultrasound terminology, which will shift from "polycystic ovarian morphology" to language that more accurately describes arrested follicles. The fundamental diagnostic approach, which combines clinical signs, hormone testing, and imaging, remains.

The Bottom Line

The renaming of PCOS to PMOS is more than a terminology update. It reflects a more accurate understanding of a condition that affects roughly 1 in 8 women across hormonal, metabolic, reproductive, and emotional dimensions of health. For people currently diagnosed with PCOS, the underlying condition has not changed, but the new name may help open conversations with clinicians beyond just gynecology. For people who have suspected they have the condition but never been evaluated, this renewed attention is a good moment to seek clinical assessment. Outputs from any AI tool, including Doctronic, are informational and not a medical diagnosis. Confirm any symptoms or concerns with a licensed clinician.

Ready to meet your AI doctor? Get started with Doctronic today.